MedTrace Logo

HA Residents With PVD, SDB Assessed at HA (2840m) vs LA (Sea Level)

NCT06072417 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2023-10-10

No results posted yet for this study

Summary

To study the effect of relocation from 2840m (Quito) to sea level (Pedernales) in patients with pulmonary vascular diseases (PVD) defined as pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension (PH) who permanently live \>2500m on sleep disordered breathing

Conditions

  • Pulmonary Vascular Disease
  • Pulmonary Artery Hypertension
  • Chronic Thromboembolic Pulmonary Hypertension

Interventions

OTHER

Assessment without intervention at High altitude

Assessments at High altitude corresponding to Baseline measures

OTHER

Relocation to sea level for 2 days

Participants will be relocated to sea level and intervention and have assessements there.

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Silvia Ulrich, Prof. Dr. · University Hospital Zurich, Departement of Pulmonology

  • Rodrigo Hoyos, Dr. · Carlos Adrade Marin Hospital of Quito, Equador

Study Design

Allocation
NON_RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-22
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06072417 on ClinicalTrials.gov